Tumor necrosis factor-alpha G-308 A polymorphism and risk of coronary heart disease and myocardial infarction: A case-control study and meta-analysis by Chu, Hongxia et al.
84 Journal of Cardiovascular Disease Research Vol. 3 / No 2
ABSTRACT
Objectives: The tumor necrosis factor-alpha (TNF-α) gene may play an important role in coronary heart disease 
(CHD) and myocardial infarction (MI) risk. Recently, controversial results regarding the association of the G-308 
A (rs1800629)polymorphism of the TNF-α gene with CHD/MI have been reported. We herein examine a possible 
association between the G-308 A (rs1800629)polymorphism of the TNF-α gene and CHD/MI in a sample of the 
Chinese Han population. Materials and Methods: We determined the genotypes of TNF-α G-308 A (rs1800629) 
in 535 unrelated Chinese patients with CHD, 420 patients with MI, and 1020 coronary artery disease-free controls. 
Additionally, a meta-analysis of all previous studies on the TNF-α G-308 A polymorphism and the risk of CHD 
and MI was performed. Results: AA genotypes in the G-308 A (rs1800629)polymorphism of the TNF-α gene did 
not occur more frequently in CHD/MI patients than in controls; odds ratios (95% confidence intervals) were 1.743 
(0.325 to 1.423) for CHD and 1.731 (0.442 to 1.526) for MI, after adjusting for conventional risk factors. Further 
stratification for age, gender, and other cardiovascular risk factors did not alter the prior negative findings. Pooled 
meta-analysis of 23 studies also found no statistically significant associations between the TNF-α polymorphism and 
CHD/MI risk in the genetic additive, dominant, and recessive models. Subgroup analyses showed no association 
between the TNF-α polymorphism and CHD/MI in Asian and Caucasian populations. Conclusion: Our study 
showed no association between the G-308 A (rs1800629) polymorphism of the TNF-α gene (presence of A allele) 
and CHD/MI in the Chinese Han population. There was no evidence of a difference in risk effects of rs1800629 
between Caucasians and Asians.
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INTRODUCTION
Coronary heart disease (CHD), one of the leading 
causes of mortality, is widely accepted as a chronic 
inflammatory disease. The immune system contributes   
to the atherosclerotic process from initiation to plaque 
rupture.[1-3] Pro-inflammatory TNF-α has repeatedly 
been found to be involved in the CHD pathological 
pathway and to be a reliable predictor of cardiovascular 
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disease. Furthermore, CHD is a complex disease that is 
multifactorial and is clearly influenced by environmental 
factors and genetic predisposition. The reported 
association of G-308 A (rs1800629) polymorphism 
of the TNF-α gene with myocardial infarction[4-7] and 
coronary artery disease[8-10] has thus generated continuing 
interest. Considering both the potential effects of the 
308 A allele on TNF-α and the putative association 
between TNF-α and cardiovascular disease, a logical 
hypothesis would be that the 308 A allele is associated 
with increased risk of cardiovascular disease. However, 
analyses of such relations have produced inconsistent 
results. Elahi et al., for example, conclude from their 
data on British CHD patients that the 308 A genotype is 
related to more severe and rapid progression of coronary 
atherosclerosis.[11,12] However, Georges et al. did not 
find any relationship between this genotype and CHD 
in a general Caucasian population.[13] Many researchers 
have tested the polymorphisms in TNF-α for genetic 
association with CHD and myocardial infarction (MI) 
and the results are controversial. To further clarify these 
inconsistent association findings and to identify the 
possible pathogenic polymorphisms in the TNF-α gene 
in relation to CHD and MI, we conducted a detailed 
association test in the Han Chinese population. To expand 
the evidence further, we performed a meta-analysis using 
published data from observational studies.
MATERIALS AND METHODS
Study population
A total of 1975 unrelated subjects, including patients 
with CHD (n = 535) and MI (n= 420), and non-coronary 
artery disease (CAD) controls (n = 1020), were enrolled 
into this study. Patients were consecutively recruited from 
Tongji Hospital and Union Hospital in Wuhan, Hubei, 
China, through October 2010. Of the total subjects, 
955 had angiographically documented severe coronary 
atherosclerosis, with a history of previous CHD/MI 
documented by combining data from clinical history 
with a thorough review of medical records showing 
diagnostic electrocardiogram and enzyme changes,   
and/or the typical sequelae of MI on ventricular 
angiography.[14] The control subjects, residing in the 
same communities as the cases, were determined to 
be free of CHD and peripheral atherosclerotic arterial 
disease by medical history, clinical examination, and 
electrocardiography. Both controls and MI cases in this 
study were genetically unrelated ethnic Han Chinese 
who provided demographic data by interview. The 
study protocol was approved by the local institutional 
review boards on human subject research, and written 
informed consent was obtained from all participants. The 
investigation conformed to the principles outlined in the 
Declaration of Helsinki.
Genotyping of polymorphisms in —Tumor necrosis 
factor alpha gene
Venous blood (7 ml) was collected from each subject into 
tubes containing 50 mmol/l Ethylenediaminetetraacetic 
acid (EDTA) (disodium salt), and genomic deoxyribonucleic 
acid (DNA) was isolated with a kit (Tiangen Biotech Co., 
Ltd., Beijing, China). The novel TNF-α polymorphism 
was genotyped using the TaqMan 5-nuclease assay on the 
TaqMan 7900HT Sequence Detection System (Applied 
Biosystems, Foster City, Calif.) under standard conditions. 
Polymerase chain reaction (PCR) reactions were carried 
out in reaction volume of 5 μl containing 5 ng DNA,   
2.5 μl 2× Taqman universal PCR Master MixNoAmpErase 
UNG (Applied Biosystems), 0.125 μl 40× Assay Mix. 
PCR conditions included 95 °C for 10 minutes, followed 
by 40 cycles of 15 seconds at 92°C and 1 minute at   
60 °C. Two blank controls (DNA hydration solution) 
and two replicate quality control samples were included 
in each 384-well format, and two replicate samples were 
genotyped with 100% concordance. The intensity of each 
single nucleotide polymorphism (SNP) met the criteria of 
three clear clusters in two scales generated by Sequence 
Detection Systems (SDS) software version 2.3 (ABI).[15]
Statistical analysis
Statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS) for Windows 
software version 12.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics were calculated for all demographic 
and clinical characteristics of the study subjects. 
Quantitative clinical data were compared between patients 
with CHD/MI and control subjects by an unpaired 
Student’s t-test. Qualitative data were compared by the 
chi-square test. Allele frequencies were estimated by the 
gene counting method, and the chi-square test was used to 
identify significant departures from the Hardy-Weinberg 
equilibrium. The strength of the association between 
the I/D polymorphism and CHD risk was measured by 
odds ratios (ORs) and 95% confidence intervals (CIs). 
In the meta-analysis, for the 308 G/A polymorphism, 
we first estimated the risk of the variant genotype A/A 
compared with the wild-type G/G homozygote (additive 
model) and then evaluated risks of A/A vs. (G/A + G/A) 
(recessive model) and (A/A + G/A) vs. G/G (dominant 86 Journal of Cardiovascular Disease Research Vol. 3 / No 2
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model). Heterogeneity was examined using the standard 
chi-square test. We considered the presence of significant 
heterogeneity at the 10% level of significance and 
values of I2 exceeding 50% as an indicator of significant 
heterogeneity. If the chi-square test for heterogeneity 
was significant, a pooled effect was calculated with a 
random-effects model, which was used to take into 
account the within-study and between-study variance. If 
the chi-square test for heterogeneity was not significant, 
a pooled effect was calculated with a fixed-effects mode. 
The meta-analysis was performed using Stata version 
10.0 (College Station, TX). All the tests were two-sided 
and the significant P -value was < 0.05. Power analysis 
was performed by Power Analysis and Sample Size 
(PASS) software (PASS version 2008, available at http:// 
www.ncss.com/pass.html).
Meta-analysis search strategy
Epidemiological genetic association studies[4,7,11,13,16-32] 
published before March 2011 on CHD/MI and the 
308 G/A polymorphisms were sought by computer-
assisted searches, using various combinations of key 
words (myocardial infarction, coronary heart disease/
coronary stenosis/coronary arterial disease, vascular/
ischemic heart/ischaemic heart, tumor necrosis factor/
TNF, gene/genetics, polymorphism/mutation/variant), 
supplemented by reviews of reference lists, hand-
searching of relevant journals, and correspondence with 
authors. Studies were included in the meta-analysis if 
genotype proportions could be obtained for controls 
and for cases of MI or coronary death. Two investigators 
independently reviewed study eligibility and extracted 
data according to a fixed protocol, with any discrepancies 
resolved by discussion. Twenty-three studies were 
included in the final analysis. Standard statistical methods 
were used to obtain inverse-variance-weighted combined 
estimates of the overall risk ratio for coronary disease/
MI with respect to these genotypes.
RESULTS AND DISCUSSION
Characteristics of patients and control subjects
The baseline characteristics of all participants are 
summarized in Table 1. The mean age of CHD and MI 
patients was not significantly different from that of the 
controls. Compared with the control group, the CHD/
MI group had a greater proportion of smokers, a higher 
average body mass index (BMI), more patients with 
hypertension and diabetes, and more males. However, 
the total cholesterol and triglyceride levels were not 
significantly higher in cases than in controls (P = 0.044,     
P = 0.035, respectively), which could be the result of patients 
taking cholesterol-lowering medication after diagnosis. 
The proportion of controls, CHD, and MI subjects who 
reported taking a cholesterol-lowering medication such as 
a statin was 0.20%, 70.48%, and 71.96%, respectively.
The genotypic and allelic frequencies of the TNF-α G-308 
A (rs1800629) polymorphism are shown in Table 2. These 
data were consistent with the distribution predicted by the 
Hardy-Weinberg equilibrium. Of the 1975 subjects, 102 
heterozygotes and 5 homozygotes for the mutant A allele 
were detected in CHD subjects, and 87 heterozygotes and 
3 homozygotes for the mutant A allele were detected in MI 
subjects, and the observed A allele frequencies were closely 
similar among the groups (10.74 % for controls, 10.47 % 
for patients with CHD, and 10.47% for patients with MI). 
The prevalence of the G/A and A/A genotypes in controls, 
patients with CHD, and patients with MI was 20.78%, 
20%, and 21.43%, respectively. Further study, stratified by 
smoking and sex, revealed no significant difference between 
the control group and each case group. Compared with 
carriers of the wild-type G/G homozygote, carriers of A 
allele (GA/AA genotypes) were not at increased risk for 
Table 1: General characteristics of coronary heart disease/myocardial infarction patients and controls who 
participated in the study
Variables Controls (n = 1020) (CHD cases) MI cases
(n = 535) P Value (n = 420) P Value
Gender, male/female, (%)
Age, years
Smoking, no/yes, (%)
HBP, no/yes (%)
Body mass index, kg/m2
Diabetes mellitus, no/yes (%)
Total cholesterol, mmol/L
Triglyceride, mmol/L
High density lipoproteins
536/484 (52.5/47.5)
53.22 ± 9.15
585/435 (57.35/42.65)
564/456 (55.29/44.71)
21.33 ± 1.65
574/446 (56.27/43.73)
4.56 ± 0.72
1.32 ± 0.44
2.87 ± 0.41
351/184 (65.6/34.4)
56.62 ± 8.33
333/202 (62.24/37.76)
349/186(65.23/44.78)
25.42 ± 2.10
330/205 (61.68/38.32)
5.35 ± 1.23
1.99 ± 0.15
3.45 ± 0.32
0.041
0.321
<0.001
<0.001
0.032
0.028
0.042
0.048
<0.001
279/141 (66.4/33.6)
59.32 ± 10.71
275/145 (65.48/34.52)
283/137 (67.38/32.62)
26.31 ± 1.98
277/143 (65.95/34.05)
6.02 ± 1.45
2.03 ±.0.21
3.71 ± 0.21
0.032
0.242
<0.001
<0.001
0.024
0.022
0.044
0.035
<0.001
Where, CHD = Coronary heart disease; MI = Myocardial infarction; HBP = High blood pressure; BMI = Body mass index.87 Journal of Cardiovascular Disease Research Vol. 3 / No 2
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CHD [Odds Ratio (OR), 0.986; 95% Confidence interval 
(CI), 0.827 to 1.104; P = 0.625], or for MI (OR, 1.011; 
95% CI, 0.965 to 1.043; P = 0.682). Moreover, the lack of 
association persisted between the AA and GG genotypes, 
as did an increased risk of CHD (AA vs. GG, OR, 1.652; 
95% CI, 0.421 to 1.736) and MI (AA vs. GG, OR, 1.711; 
95% CI, 0.432 to 1.255), and of CHD (GA and AA vs. 
GG, OR, 1.743; 95% CI, 0.325 to 1.423) and MI (GA and 
AA vs. GG, OR, 1.731; 95% CI, 0.442 to 1.526) even after 
controlling for other conventional risk factors by multiple 
logistic regression [Table 2].
As shown in Table 3, there were no significant associations 
between the rs1800629 and sex, age, BMI, proportions 
of hypertension, diabetes mellitus, or smoking status in 
CHD/MI patients or controls. To evaluate the impact of 
age on the association of the rs1800629 variant and CHD/
MI, the samples were divided into two groups based on 
the median age of controls (≤ 60 and > 60 years). No 
significant difference of genotype distribution (P = 0.618 
and P = 0.633, respectively) between CHD/MI patients 
and controls was observed in any of the groups [Table 3]. 
Further study, stratified by smoking and gender, revealed 
no significant difference between the control group and 
each case group (data not shown), even after adjusting by 
multiple logistic regression for other conventional risk 
factors, such as gender, smoking, BMI, hypertension, and 
diabetes.
Meta-analysis results
Table 4 shows the characteristics of studies included in this 
meta-analysis. The association between the A/A genotype 
compared with the G/G genotype and CHD/MI risk 
showed no significance utilizing the random-effects model 
(OR, 0.90; 95% CI, 0.74–1.09; P = 0.006). Additionally, no 
Table 2: Association of rs1800629 with coronary heart disease/myocardial infarction Cases and Controls in the 
Chinese Han Population as observed in the study
TNF-α 308 G/A 
Genotype
Controls 
number (%)
CHD cases MI cases
Number 
(%)
OR* (95% CI) P value Number (%) OR* (95% CI) P value
GG
GA
AA
GA and AA
Alle
808
205
7
212
79.22
20.09
0.69
20.78
428
102
5
107
80
19.06
0.94
20
1.000
1.628 (0.358-1.742)
1.652 (0.421-1.736)
1.743 (0.325-1.423)
0.547
0.718
0.721
330 78.57
87 20.71
3  0.71
90 21.43
1.000
10.611 (0.472-1.580)
1.711 (0.432-1.255)
1.731 (0.442-1.526)
0.631
0.695
0.703
G 1821 89.26 958 89.53 1.000 747 88.93 1.000
A 219 10.74 112 10.47 0.986 (0.827-1.104) 0.625 93 11.07 1.011 (0.965-1.043) 0.682
NC, not calculated, *: Adjusted for sex, age, BMI, DM, and smoking status. Where, CHD = Coronary heart disease; MI = Myocardial infarction; OR = Odds ratio; CI = Confidence 
interval.
Table 3: Stratification Analysis for Association between rs1800629 and Risk of coronary heart disease/ 
myocardial infarction
TNF-α 308 G/A 
Genotype
GG CHD cases MI cases
GA OR (95% CI)* AA OR (95% CI)* P value GA OR (95% CI)* AA OR (95% CI)* P value
Gender 1.000 1.000
Male 1.000 1.210 (0.522-3.929) 1.543 (0.214-1.376) 0.858 1.507 (0.515-3.654) 0.926 (0.583-1.471) 0.758
Female 1.000 1.133 (0.203-2.414) 0.855 (0.550-3.340) 0.157 1.944 (0.584-2.526) 0.543 (0.214-1.376) 0.208
Age, years 1.000
≤ 60 1.000 1.973 (0.488-2.345) 0.248 (0.218-2.787) 0.618 1.353 (0.476-2.604) 0.855 (0.550-1.330) 0.389
> 60 1.000 1.486 (0.515-2.156) 0.655 (0.199-1.159) 0.633 1.617 (0.226-2.680) 1.766 (0.241-2.180) 0.174
Smoke status 1.000
Nonsmokers 1.000 1.596 (0.567-2.228) 0.5419 (0.175-2.004) 0.203 1.238 (0.567-2.228) 1.474 (0.150-2.498) 0.294
Smokers 1.000 0.807 (0.168-1.937) 0.401 (0.163-1.992) 0.579 0.807 (0.129-1.914) 0.819 (0.519-1.291) 0.262
Hypertension 1.000
No 1.000 1.953 (0.568-2.341) 0.252 (0.065-2.779) 0.485 1.473 (0.510-2.495) 1.668 (0.151-2.292) 0.071
Yes 1.000 0.7512 (0.332-1.151) 0.277 (0.112-1.591) 0.294 0.891 (0.553-1.434) 0.491 (0.593-1.478) 0.663
Diabetes 1.000
No 1.000 1.025 (0.727-2.756) 0.507 (0.155-1.654) 0.202 1.644 (0.116-2.592) 1.584 (0.234-2.465) 0.741
Yes 1.000 0.926 (0.583-1.471) 0.944 (0.584-1.567) 0.708 0.493 (0.185-1.312) 0.535 (0.261-1.413) 0.469
*ORs were obtained from a logistic regression model with adjustment for age, sex, smoking, BMI, hypertension, and diabetesWhere, CHD = Coronary heart disease; MI = Myocardial 
infarction; OR = Odds ratio; CI = Confidence interval88 Journal of Cardiovascular Disease Research Vol. 3 / No 2
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Table 4: Meta-analysis of rs1800629 and risk of coronary heart disease/myocardial infarction in the patients in the study
Groups Number of studies Statistical methods Genetics models OR (95%CI) I-Square P value
All studies 23 Fixed Additive 0.90 (0.74-1.09) 49.1% 0.006
Fixed Dominant 1.01 (0.95-1.06) 39% 0.030
Random Recessive 1.00 (1.00-1.01) 61.9% < 0.001
Caucasian 16 Random Additive 0.89 (0.72-1.09) 58% 0.002
Random Dominant 1.01 (0.95-1.07) 51.8% 0.008
Random Recessive 1.00 (1.00-1.01) 68.4% < 0.001
CHD 7 Random Additive 0.88 (0.63-1.23) 77.0% < 0.001
Fixed Dominant 1.00 (0.90-1.11) 31.2% 0.179
Random Recessive 1.01 (0.99-1.02) 83.7% < 0.001
MI 8 Fixed Additive 0.86 (0.66-1.13) 10.3% 0.350
Fixed Dominant 1.00 (0.93-1.08) 49.3% 0.055
Fixed Recessive 1.00 (1.00-1.01) 31.2% 0.179
CHD and MI 1 --- Additive 2.86 (0.49-16.78) --- ---
--- Dominant 1.39 (0.85-2.26) --- ---
--- Recessive 0.98 (0.95-1.02) --- ---
Asian 7 Fixed Additive 0.97 (0.61-1.53) 0 0.465
Fixed Dominant 1.00 (0.83-1.21) 0 0.550
Fixed Recessive 1.00 (0.99-1.02) 0 0.426
CHD 5 Fixed Additive 0.93 (0.58-1.49) 0 0.403
Fixed Dominant 1.02 (0.82-1.27) 12.3% 0.335
Fixed Recessive 1.00 (0.98-1.02) 18.2% 0.300
CHD and MI 2 --- Additive 3.31 (0.14-8.78) 0 < 0.001
--- Dominant 0.96 (0.65-1.40) 0 < 0.001
--- Recessive 1.00 (0.98-1.01) 0 < 0.001
Where, CHD = Coronary heart disease; MI = Myocardial infarction; OR = Odds ratio; CI = Confidence interval.
Figure 1: Associations between G-308 A (rs1800629) polymorphism of the TNF-α gene and  risk of CHD/MI were not observed89 Journal of Cardiovascular Disease Research Vol. 3 / No 2
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significant association was demonstrated in the dominant 
model (OR, 1.01; 95% CI, 0.95–1.06; P = 0.30). However, 
this association was significant in the recessive model 
(OR, 1.00; 95% CI, 1.00–1.01; P< 0.001). No significant 
heterogeneity was present in any of the models (additive 
model I2 = 49.1%, recessive model I2 = 39%, and dominant 
model I2 = 61.9%).
DISCUSSION
CHD occurs as a consequence of a pathological process 
that can be triggered and enhanced by inflammation.[20,33-35] 
Both environmental and genetic risk factors are likely 
mediators of pathogenesis of this disease. On the basis of 
the hypothesis that coronary atherosclerosis is a chronic 
inflammatory disease, we examined the relationship between 
the G-308 A (rs1800629) polymorphism and the risk of 
CHD/MI. Our data showed that the G-308 A (rs1800629) 
polymorphism in the TNF gene was not associated with 
CHD/MI in the Chinese Han population. The carriers of 
the A allele were not found to have a higher risk of CHD/
MI than the carriers of the G allele,[18] a finding which 
agrees with that of the present meta-analysis in Asians and 
Caucasians. Although a case-control study identified TNF-α 
SNP (308 G/A (rs1800629) associated with CHD/MI risk 
among Italian participants,[18] confirmation of these results 
has been mixed. We used twenty-three primary studies 
for meta-analysis, and the results indicated that there was 
no association between the TNF G-308 A (rs1800629) 
polymorphism and risk of CHD and MI as show in   
Figure 1. A large sample-size study has more statistical 
power than a small-scale study and can effectively avoid 
potential bias. Thus, our meta-analysis was based on a large 
sample size, which greatly enhanced the statistical power 
compared to that of a single primary study, and ensured 
the reliability of the results. Our present case-control 
study and meta-analysis of subsequent studies concluded 
that common TNF-α polymorphisms are not strongly 
associated with CHD/MI susceptibility, contributing 
additional evidence for the lack of association between 
G-308 A (rs1800629)and CHD/MI risk among our study 
population.
The present report demonstrates the potential for large-
scale genetic epidemiology to help assess the nature 
of relationships between putative risk factors and   
disease.[36] It had not previously been possible to determine 
with certainty whether the observed association between 
the G-308 A (rs1800629) polymorphism in the TNF gene 
and CHD/MI risk was causal, or due to residual biases 
from incomplete adjustment for all potential risk factors. 
However, adjustment for the factors measured in this study 
did not greatly affect the negative results. After adjusting 
for sex, age, BMI, diabetes mellitus, and smoking status, 
the results indicated that A allele was not associated with an 
increased risk of CHD and MI. This result is inconsistent 
with the results of studies conducted by Dedoussis[22] and 
Giacconi[23] et al. No association was found in the present 
study between rs3025058 and CHD/MI in a meta-analysis 
of Asian populations or in a meta-analysis of Caucasian 
populations.
The inconsistency of these results may have several 
explanations. First, to study interactions, the present model 
required large sample sizes to obtain acceptable statistical 
power, and single interaction effects may be too small 
to be detected. According to power analysis, our study 
had greater than 80% and 75% power to detect effects 
of TNF-α polymorphism (rs1800629) on CHD and MI, 
respectively, assuming an OR of 1.5. Second, the exclusion 
of fatal cases in this study is a possible limitation. The 
exposures under study, especially the genetic exposure, 
may be strong associated factors with a fatal outcome of 
MI, although this could not be detected in this study. We 
genotyped the SNP and did not observe associations with 
CHD/MI; however, our study was limited to survivors 
of incident events, and potential stronger associations in 
CHD were found among the fatal cases. Third, due to the 
lack of individual patient data, we could not conduct an 
adjustment estimate by sex, age, BMI, diabetes mellitus, and 
smoking status information. Finally, genetic variations not 
only modulate some of these classical cardiovascular risk 
factors, but also act also in a complex manner.
In conclusion, we found no evidence to support the 
theory that the presence of the 308 A allele at the G-308 
A (rs1800629) polymorphism of the TNF-α gene variation 
in CHD/MI was related to an increased risk of CHD/
MI among the Chinese Han population. Furthermore, we 
found no evidence that the presence of the 308 A allele 
would interact synergistically with environmental factors, 
such as hypertension, type 2 diabetes, obesity, and smoking, 
studied in causing CHD/MI.
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